Can we predict who will respond to immunotherapy for pancreatic cancer?
NCT ID NCT07271823
First seen Jan 06, 2026 · Last updated Jun 05, 2026 · Updated 21 times
Summary
This study aims to create a model that predicts how well patients with advanced pancreatic cancer will respond to immunotherapy. Researchers will collect tumor tissue, blood, and stool samples from 100 patients to analyze proteins, metabolites, and gut bacteria. The goal is to improve treatment decisions by identifying which patients are most likely to benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Zhejiang, Hangzhou, 310022, China
Conditions
Explore the condition pages connected to this study.